Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2026
  • August
  • 27
  • The Multiple Already Halved. Now Comes the Hard Data.
  • Economy

The Multiple Already Halved. Now Comes the Hard Data.

With AFRM’s forward P/E now in the mid-30s and Klarna’s Europe-driven stumble fresh, tonight’s fiscal Q4 report is where a compressed valuation meets a credit scare it did not cause, and where the options market may be underpricing the gap risk.
Market Spectator August 27, 2026 4 minutes read
24d5a09c-6295-4167-8e6a-01429b8dcf42

Most of tonight’s AFRM coverage is framing this as a credit story. It is not, or at least not in the way the market fears. The more actionable question is about mispriced options on a stock whose multiple has already absorbed a punishment Affirm did not earn.

Affirm’s forward P/E has roughly halved since earlier this year, even as Affirm’s own fundamentals have been improving. The culprit was Klarna. Reuters reported Aug. 18, 2026, that Klarna cut its full-year volume and revenue forecast, citing conditions in Germany, its largest market by volume. That is a European macro problem, not a BNPL credit problem. On the day Klarna dropped roughly 19%, at least one market recap noted Affirm was essentially flat, suggesting traders initially treated the shock as company-specific. The sector did not break. The multiple on Affirm did anyway.

That divergence is the foundation of tonight’s trade.

What the Numbers Say Going In

Affirm is set to report its fiscal Q4 2026 results after the bell today, with consensus at about $0.33 EPS on revenue of roughly $1.11 billion. The consensus GMV estimate implies roughly 29% growth from the prior-year quarter, with management’s own guidance pointing to $13.15–$13.45 billion.

Credit quality is the wild card, but the data available cuts against the bear case. In its fiscal Q3 2026 shareholder letter, Affirm reported 30+ day delinquencies for its monthly installment loan portfolio holding around 2.5%–3.0% across recent quarters, including 2.8% at March 31, 2026, and it has pointed to competitor ranges of roughly 3.5%–5.5%. The 2.8% delinquency figure entering this quarter represents the benchmark investors will stress-test tonight. Separately, BTIG flagged elevated early-stage delinquencies in Affirm’s ABS static pools, with 30–59 day readings at all-time highs for newer vintages, a real watch item, though BTIG also noted that higher losses may be acceptable as long as RLTC margins stay in range and GMV accelerates.

Why the Options Market May Be Getting This Wrong

The market has priced in an earnings reaction of roughly plus or minus 12%–13%. That sounds elevated until you look at what happened the last time a BNPL peer reported into a scare: Klarna’s guidance cut sent that stock down roughly 17% in premarket trading, with some market coverage describing a roughly 19% drop during the session. Affirm tonight faces a different problem: even a clean beat may not fully offset a stock still carrying the overhang of contagion fears it never earned.

The implied move of around 13% has a skew problem. A miss on delinquency commentary or forward guidance could trigger a gap well beyond that range. This is an early-cycle US datapoint on BNPL credit, and the market does not yet have a stable framework for pricing it. Conversely, a clean quarter with tight delinquencies would validate the thesis that Klarna’s problems are geography-specific, which could produce a sharp reversal from a compressed multiple. Ahead of tonight’s report, Oppenheimer raised its price target on Affirm to $100 from $87.

The Strategy

The asymmetry here favors two defined-risk structures depending on conviction direction.

For bulls: a call debit spread targeting a move toward $88–$92 captures the re-rating that follows a clean beat. Buying the at-the-money call and selling a strike near $90 keeps the premium outlay well inside the implied move, so a trader is not paying the full vol crush that hits naked long calls after earnings. The rationale is that full-year fiscal 2026 revenue consensus of $4.21 billion implies 30.5% growth on a stock now trading near the mid-30s forward P/E, a multiple that leaves meaningful room for upside if guidance holds.

For those concerned the implied move understates downside: a put debit spread, buying a put near the money and selling a lower strike, defines the risk while exploiting any gap down driven by credit commentary rather than fundamentals. The Klarna precedent shows that BNPL stocks can move far beyond the options market’s implied range when a new credit data point surprises.

The Beast Verdict

Tonight’s Affirm report is a rare event-driven situation where the multiple compression has already happened, the credit scare originated elsewhere, and the options market is pricing an implied move that may be too narrow for the credit-driven tail. The defined-risk structure matters here precisely because the range of outcomes is unusually wide: a clean quarter re-rates a stock sitting at roughly half its prior forward multiple; a credit miss triggers the contagion trade the market has been fearing since Klarna cut guidance.

Position size accordingly. The opportunity is in the skew, not the direction.

Post navigation

Previous: Three Years Down. Is Pernod’s Dividend Next?

Related Stories

d008a8b2-9c64-4d02-b4b5-e472b3512d93
  • Economy

Your T-Bill Ladder Has a New Ally

Market Spectator August 26, 2026
6c52032a-a4a8-4816-8eba-e4c2b0684d86
  • Economy

WMT Dropped 9% on a Guidance Raise

Market Spectator August 23, 2026
94429b82-f296-4fec-a5ca-da97f39d7d66
  • Economy

Nike Is Repeating Its Worst Mistake

Market Spectator August 18, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

  • The Multiple Already Halved. Now Comes the Hard Data.
  • Three Years Down. Is Pernod’s Dividend Next?
  • Your T-Bill Ladder Has a New Ally
  • From $25B to $55B: Moderna’s Melanoma Math
  • The September Countdown Is Already Priced Wrong
  • The September Countdown Is Already Priced Wrong
  • What a $150M PIPE Into a Sub-$1 Shell Actually Says

Categories

  • Business
  • Economy
  • Money
  • Politics
  • Top News

You may have missed

24d5a09c-6295-4167-8e6a-01429b8dcf42
  • Economy

The Multiple Already Halved. Now Comes the Hard Data.

Market Spectator August 27, 2026
fd92cbe4-f6e4-41ca-b34f-3b7a1bee75dc
  • Business

Three Years Down. Is Pernod’s Dividend Next?

Market Spectator August 27, 2026
d008a8b2-9c64-4d02-b4b5-e472b3512d93
  • Economy

Your T-Bill Ladder Has a New Ally

Market Spectator August 26, 2026
7e996894-a577-4b83-ab8e-c1d78ecf17ce
  • Politics

From $25B to $55B: Moderna’s Melanoma Math

Market Spectator August 26, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Market Spectator | marketspectator.com SITE_OK